| Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations (NCT04550494) | National Cancer Institute (NCI) | 2021-04-26 |
| Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation (NCT04390243) | Academic and Community Cancer Research United | 2020-11-16 |
| Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer (NCT03257761) | University of Southern California | 2018-02-07 |
| Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer (NCT03095781) | Emory University | 2017-07-07 |
| APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery (NCT03087591) | Wake Forest University Health Sciences | 2017-04-28 |
| FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer (NCT02890355) | National Cancer Institute (NCI) | 2016-10-27 |
| Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery (NCT02896907) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2016-10-18 |
| Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer (NCT03073785) | University of Nebraska | 2016-09-16 |
| TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors (NCT02650635) | Mayo Clinic | 2016-02-05 |
| BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer (NCT02620865) | Barbara Ann Karmanos Cancer Institute | 2015-12-01 |
| Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer (NCT02451553) | University of Washington | 2015-11-05 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCT02465060) | National Cancer Institute (NCI) | 2015-08-17 |
| Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer (NCT02349867) | Virginia Commonwealth University | 2015-01-29 |
| Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery (NCT01783171) | National Cancer Institute (NCI) | 2013-01-15 |
| Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction (NCT01638533) | National Cancer Institute (NCI) | 2012-08-03 |
| Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy (NCT01658943) | National Cancer Institute (NCI) | 2012-08-01 |
| Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery (NCT01660971) | National Cancer Institute (NCI) | 2012-07-30 |
| Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer (NCT01280058) | National Cancer Institute (NCI) | 2010-12-01 |
| Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer (NCT01195415) | National Cancer Institute (NCI) | 2010-06-01 |
| Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors (NCT01131234) | National Cancer Institute (NCI) | 2010-05-01 |
| Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer (NCT01064622) | National Cancer Institute (NCI) | 2009-09-03 |
| GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery (NCT00878163) | National Cancer Institute (NCI) | 2009-03-31 |